Novel monoclonal antibody therapy shows promising results in patients with moderate to severe atopic dermatitis


Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab-;a novel, patient-tailored monoclonal antibody therapy-;showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet.

How kids can cope with holiday stress

Previous article

Multiple Amazon Kindle deals are here to help you kickstart a reading habit

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News